Kazia Therapeutics Annual Report 2021

STATEMENT OF CASH FLOWS For the year ended 30 June 2021 2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 41 Consolidated Note 2021 2020 $ $ Cash flows from operating activities Receipts from customers * 13,739,254 - Payments to suppliers (inclusive of GST) (23,868,218) (10,200,368) R&D cash rebate 1,018,448 1,390,849 Net cash used in operating activities 30 (9,110,516) (8,809,519) Net cash from investing activities - - Cash flows from financing activities Proceeds from issue of shares - net of issuance costs 17 28,108,848 12,139,695 Net cash from financing activities 28,108,848 12,139,695 Net increase in cash and cash equivalents 18,998,332 3,330,176 Cash and cash equivalents at the beginning of the financial year 8,764,044 5,433,868 Effects of exchange rate changes on cash and cash equivalents (175,616) - Cash and cash equivalents at the end of the financial year 9 27,586,760 8,764,044 * Receipts from customers were subject to deduction of VAT and withholding tax at source. The above statement of cash flows should be read in conjunction with the accompanying notes